Medical Articles 2/23
Posted by rob on February 23, 2009 under Uncategorized | 
Be the First to Comment
A Worldwide Support Network For Chronic Myelogenous Leukemia
Archives
- February 2012
- January 2012
- October 2011
- September 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- February 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- July 2006
- June 2006
- May 2006
- April 2006
- March 2006
- February 2006
- January 2006
- December 2005
- November 2005
- October 2005
- September 2005
- August 2005
- July 2005
- June 2005
- May 2005
- April 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
- July 2004
- June 2004
Recent Posts
- Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
- Caregiving Burden, Stress, and Health Effects Among Family Caregivers of Adult Cancer Patients [Grand Rounds]
- Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
- Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
- Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
- Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
- Imatinib and beyond – targeting activated tyrosine kinases in myeloproliferative disorders.
- Recent developments and future perspectives of personalized oncology.
- [Mechanism of cinnamic aldehyde-inducing apoptosis of chronic myeloid leukemic cells in vitro].
- [Expression of CIAPIN1 gene in BMMNC of patients with leukemia].
- Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells
- CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression
- Perspectives on Targeted Therapies for Treatment of Human Cancers: Predictors of Response to Targeted Therapies for Gastrointestinal Stromal Tumors.
- Modeling of Molecular Interaction between Apoptin, BCR-Abl and CrkL – An Alternative Approach to Conventional Rational Drug Design.
- Ponatinib: Targeting the T315I Mutation in Chronic Myelogenous Leukemia.